Overview of Amphetamine Sulfate

Property	Description
Active ingredient	Amphetamine Sulfate (racemic mixture)
Form	Tablets (Immediate-release, extended-release)
Pharmacological class	Central Nervous System (CNS) Stimulant, Psychoanaleptic
General purpose	Enhancing attention and promoting wakefulness
Origin	Synthetic

What Type of Medicine Is Amphetamine Sulfate?

Amphetamine Sulfate is a synthetic medication classified as a Central Nervous System (CNS) Stimulant and a psychoanaleptic. This drug entity is chemically defined as a sulfate salt of amphetamine, belonging to the phenethylamine class of compounds, which are often characterized as sympathomimetic amines. Its identity is formally recognized for therapeutic use, and it is classified as a Schedule II controlled substance due to its abuse potential and established medical utility. This classification confirms this medicine is a legally recognized treatment option for specific conditions.

The pharmacological classification signifies that Amphetamine Sulfate's fundamental identity is rooted in its ability to directly influence neurochemical processes. As a synthetic compound, it is manufactured for therapeutic purposes and is clinically recognized for its potent CNS effects supported by pharmacological studies. Its function as a CNS stimulant involves boosting activity in the neural pathways responsible for focus and cognitive control.

Composition, Form, and General Purpose

The active ingredient, Amphetamine Sulfate, is a racemic mixture composed of equal parts of the two stereoisomers: dextroamphetamine and levoamphetamine. This specific blend, known as pm-Amphetamine sulfate, dictates its overall pharmacological effect, providing a balance between the potent d- form and the more peripherally active l- form. The medication is prepared for oral administration, primarily available in tablets formulated as either immediate-release or extended-release forms.

These formulations are designed to achieve the drug's general therapeutic purpose: enhancing the brain's ability to maintain attention and improving wakefulness—a critical benefit for addressing conditions characterized by excessive drowsiness. The underlying mechanism involves promoting the release and blocking the reuptake of chemical messengers, particularly dopamine and norepinephrine, thereby enhancing signal transmission in the parts of the brain controlling concentration. Amphetamines increase dopamine and norepinephrine levels in the brain. This core action involves boosting these key brain chemicals. This action is leveraged to support sustained focus in individuals experiencing certain cognitive deficits or pathological sleepiness.

Regulatory References

FDA label and Schedule II classification for Amphetamine Sulfate

What side effects are possible with Amphetamine Sulfate?

The safety profile of Amphetamine Sulfate, as outlined in regulatory labeling, is focused on risks associated with its action as a Central Nervous System (CNS) Stimulant. The adverse reactions are formally classified by the organ systems affected.

Documented Adverse Reactions

Adverse effects commonly reported in regulatory documents involve the Gastrointestinal/Metabolic system (e.g., loss of appetite, weight loss, dry mouth), the Nervous System (e.g., headache, tremor, dizziness), and Psychiatric function (e.g., insomnia, agitation, anxiety). The official profile notes the possibility of psychotic episodes occurring at usual doses.

Cardiovascular effects are a primary concern, including tachycardia (increased heart rate), palpitations, and blood pressure elevation.

Serious Safety Considerations

The regulatory labeling highlights risks for serious adverse reactions, including reports of Sudden Death in pediatric patients with pre-existing structural cardiac abnormalities. In adults, stroke and myocardial infarction have been reported with stimulant use. The profile also notes the potential for Serotonin Syndrome when this medicine is used alongside other serotonergic agents, a high-level safety consequence documented in official sources.

Population and Duration-Related Safety

Specific safety considerations apply to certain groups. In pediatric patients receiving prolonged treatment, the risk of long-term growth suppression (affecting weight and height) is documented. For all patients, the official profile notes the potential for tolerance and psychological dependence with prolonged administration. The medicine is contraindicated in patients with specific conditions, including symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, and a history of drug abuse.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

Overdose with Amphetamine Sulfate is characterized by an extreme extension of its pharmacological actions, primarily affecting the Central Nervous System (CNS) and the cardiovascular system. Due to the high risk of serious toxicity, regulatory bodies mandate specific, immediate actions.

Manifestations and Outcomes	Regulatory Description
Documented Manifestations	Symptoms include restlessness, tremor, hyperreflexia, rapid respiration, confusion, hallucinations, hyperpyrexia, and gastrointestinal effects like nausea and abdominal cramps. Cardiovascular signs include palpitations, arrhythmias, and severe hypertension or subsequent hypotension.
Severe Complications	Overdose can result in life-threatening events such as seizures, coma, myocardial infarction, cerebral hemorrhage, rhabdomyolysis, and circulatory collapse.

Emergency Action and Management

Emergency medical care must be sought immediately if an overdose is suspected or confirmed. Management is symptomatic and supportive, as no specific antidote is known for acute intoxication. Due to the severe risk of cardiovascular events, hospitalization with continuous cardiac monitoring is often required. Procedures such as gastric lavage or the use of activated charcoal may be considered. Severe CNS effects, including convulsions or marked excitement, may require the use of intravenous benzodiazepines as supportive treatment.

Therapeutic Uses of Amphetamine Sulfate

The therapeutic applications for Amphetamine Sulfate focus on providing supportive symptomatic management across distinct neurological and metabolic domains.

Amphetamine Sulfate is commonly used to help with symptom clusters that create noticeable functional strain in chronic conditions. These conditions primarily include neurodevelopmental disorders associated with inattention and impulsivity, chronic sleep-wake regulation disorders causing pathological sleepiness, and, in a short-term capacity, managing excessive appetite for medically supervised weight reduction.

Core Symptomatic Relief

This medication is applied across domains where additional symptomatic support is needed. For attention-deficit symptoms, it helps address deficits in focused attention and behavioral dysregulation. For sleep disorders, it may assist with promoting sustained wakefulness, which helps ease the overall symptom burden of unpredictable drowsiness. The goal of symptomatic relief is to assist with maintaining functional stability.

“The support provided may assist with maintaining functional stability and helps improve day-to-day comfort during symptomatic periods.”

Quick Fact: Relevant for Managing Pathological Drowsiness

Amphetamine Sulfate is relevant in conditions characterized by symptoms of increased neurological activity, supporting patients during episodes of overwhelming excessive daytime sleepiness.

Regulatory References

NIH DailyMed - Amphetamine Sulfate Labeling

Eligibility and Restrictions for Use

Who Can and Cannot Use Amphetamine Sulfate?

Regulatory authorities define strict population-based rules for the use of Amphetamine Sulfate, focusing on patient health status and life stage.

Absolute Contraindications

Amphetamine Sulfate must not be used by patients with specific pre-existing conditions or pharmacological histories. These absolute prohibitions include individuals with:

Symptomatic cardiovascular disease, moderate to severe hypertension, or advanced arteriosclerosis.
Hyperthyroidism or glaucoma.
Agitated states or a known history of drug abuse.
Known hypersensitivity to amphetamine or sympathomimetic amines.
Use of a Monoamine Oxidase Inhibitor (MAOI) within 14 days prior to treatment.

Age and Physiological Restrictions

Population Group	Eligibility Status
Children	Approved for use in children aged 6 years and older for most indications, with some specific formulations approved down to age 3. Use is not established in children under 3.
Older Adults	Use is not established; caution is recommended due to potential for age-related cardiac or renal risks.
Pregnancy/Lactation	Use during pregnancy may cause fetal harm; use is permitted only if the benefit outweighs the risk. Breastfeeding is not recommended as the drug is excreted into human milk.

Conditional Use

Patients with severe renal impairment (ESRD) are generally not recommended for treatment. Caution is required and use is conditional for patients with pre-existing psychosis, Bipolar Disorder, or a history of seizures, as symptoms may be exacerbated.

What should I know about interactions with other medicines?

Amphetamine Sulfate has officially documented interaction patterns that influence its use with other medicines and products. The most significant restriction is the strict prohibition of co-administration with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and Methylene blue injection. A mandatory 14-day separation period must be completed following the discontinuation of an MAOI to avoid the risk of a hypertensive crisis.

Interactions based on pharmacokinetics involve both enzymatic inhibition and pH changes. Co-administration with CYP2D6 inhibitors, such as Paroxetine and Fluoxetine, may increase the plasma concentration (exposure) of amphetamine due to reduced metabolic clearance. The pH of the gastrointestinal tract and urine also alters drug exposure. Acidifying agents, including certain fruit juices and Vitamin C (Ascorbic Acid), reduce absorption and increase excretion, resulting in lower blood levels and reduced efficacy. Alkalinizing agents, such as Sodium Bicarbonate, increase absorption and decrease excretion, thereby potentiating the drug's action.

Pharmacodynamic interactions result in additive or opposing effects. Combining amphetamine with other serotonergic drugs significantly increases the documented risk of Serotonin Syndrome. Furthermore, the drug may antagonize the intended hypotensive effects of certain antihypertensive medications. The regulatory label also notes that consumption of alcohol may increase the risk of serious cardiovascular side effects.

Mechanism of Action

Reverse Transport and Synaptic Efflux

The core mechanism involves the drug acting on the Dopamine (DAT) and Norepinephrine (NET) transporters, forcing them to operate in reverse while simultaneously disrupting the Vesicular Monoamine Transporter 2 (VMAT2) storage mechanism. This molecular action bypasses normal release cycles and results in a large, rapid, and sustained surge of neurotransmitters into the synapse, which establishes the subsequent physiological effects.

Modulation of Arousal and Cognitive Pathways

The resulting high concentrations of Dopamine and Norepinephrine strongly stimulate two major central systems: Dopamine enhances signaling in the prefrontal cortex and associated pathways for executive function circuits, while Norepinephrine activates the Ascending Reticular Activating System (ARAS) for enhanced arousal. This simultaneous activation of attention and vigilance pathways contributes to the resulting central nervous system activity profile.

Stereoisomer Synergy and Physiological Balance

Amphetamine Sulfate is a racemic mixture of d- and l-isomers, which exhibit differential activity: the d-isomer is more potent at the DAT, primarily supporting cognitive pathway activity, and the l-isomer contributes more strongly via the NET (driving arousal and peripheral stimulation). The blend facilitates both central monoaminergic modulation and systemic physiological activation.

Dosage and Administration Information

How to Use Amphetamine Sulfate

Amphetamine Sulfate is administered via the oral route, primarily in the form of Immediate-Release (IR) tablets. The administration protocol is defined by a structured regimen based on gradual dose adjustment and precise timing.

Administration and Timing Principles

The medication is typically taken daily in divided doses to maintain steady levels throughout the day. The first dose is taken upon awakening in the morning, with subsequent doses administered at intervals of 4 to 6 hours. General guidance suggests that late evening doses should be avoided to prevent interference with sleep, establishing a time-of-day constraint on its use.

For the exogenous obesity indication, a specific contextual rule applies: the doses must be administered 30 to 60 minutes before meals. Standard IR tablets are designed to be swallowed whole.

Labeled Dosing and Duration Patterns

The initial treatment strategy involves titration, where therapy begins at a low daily amount and is gradually increased in small increments, often 2.5 mg or 5 mg, at weekly intervals until the optimal dose is identified.

Administration patterns are differentiated by indication:

Indication	Initial Dosing	Duration Pattern
Narcolepsy	≥10 mg daily (divided)	Used long-term
ADHD	≥5 mg once or twice daily	Requires occasional interruption to assess necessity
Exogenous Obesity	5 mg to 10 mg (divided)	Short-term adjunct (a few weeks)

Age-Specific Rules: Dosing is adjusted for pediatric patients. For example, children 3 to 5 years old for ADHD begin at 2.5 mg daily, with weekly increases limited to 2.5 mg increments. Use in children under 3 years for ADHD and under 12 years for obesity is not recommended.

Recent Clinical Evidence

Research exploring the use of Amphetamine Sulfate, a Central Nervous System stimulant, for conditions such as Attention-Deficit/Hyperactivity Disorder (ADHD) primarily involves short-term randomized controlled trials (RCTs) and systematic reviews. These studies monitor symptoms that reflect daily functioning and activity level in children, adolescents, and adults. Findings describe patterns observed in these short-term trials related to how symptom measurements evolved in the observed populations, utilizing standardized clinical rating scales. However, the core evidence base for ADHD is limited to outcomes observed over short time intervals, typically a few weeks to months, and methodological approaches vary across studies.

For Narcolepsy, the evidence base includes older clinical trials and clinical reviews. Research has examined whether the medication was associated with changes in objective tests that measure sleep tendency and subjective scales that track perceived levels of sleepiness. The key uncertainty for this indication is the lack of modern, large-scale, placebo-controlled studies focusing specifically on this compound, alongside limited context regarding long-term impact on the condition.

The medication was evaluated in short-term clinical trials as an adjunct to diet for Exogenous Obesity, focusing on measures of weight loss and appetite suppression. The results apply only to the short study durations and the specific populations examined.

Across all indications, a critical limitation is that follow-up durations were limited in most gold-standard, controlled trials. As a result, long-term effects are not fully established, and there is limited information regarding the maintenance of symptom changes over many years. Furthermore, while research exists for children and adults, data for certain groups remain insufficient, especially focusing on geriatric populations or individuals with complex co-occurring medical conditions. Subgroup findings are often uncertain, meaning research provides context about group patterns but not individual predictions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Amphetamine Sulfate (FAQ)

Q: What is the main condition Amphetamine Sulfate is officially approved to treat?

A: Official product labeling indicates that Amphetamine Sulfate is approved for three main uses. These include the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Narcolepsy. It is also approved as a short-term adjunct for Exogenous Obesity when combined with diet.

Q: Is it possible for Amphetamine Sulfate to interact with over-the-counter medications?

A: Yes, official drug interaction information notes that the effects of this medication can be influenced by other substances, including certain over-the-counter products. For instance, products that make urine more acidic (such as Vitamin C) may reduce the systemic exposure of the drug, while agents that make urine more alkaline (such as sodium bicarbonate found in some antacids) may increase the systemic exposure of the drug.

Q: What does 'tolerance' mean in the context of taking Amphetamine Sulfate?

A: The regulatory labeling notes the potential for tolerance with prolonged administration. Tolerance refers to the body requiring a higher amount of the substance over time to achieve the original effect, which is why the medicine carries a warning about potential psychological dependence.

Q: Why is there a risk of misuse or dependence associated with Amphetamine Sulfate?

A: Official documentation, including the Boxed Warning, states that amphetamines have a high potential for abuse and may lead to drug dependence with prolonged use. This potential for misuse is linked to the risk of serious health consequences, including sudden death and severe cardiovascular events.

Q: Can Amphetamine Sulfate be taken with antidepressants?

A: Regulatory documents state that use is strictly contraindicated with Monoamine Oxidase Inhibitors (MAOIs). Caution is also advised regarding other types of antidepressants, specifically serotonergic drugs and CYP2D6 inhibitors, due to the documented risk of conditions like Serotonin Syndrome or increased exposure to amphetamine.

Q: Do the effects of Amphetamine Sulfate change over time?

A: Official product warnings indicate that the therapeutic effects may change over time due to the risk of developing tolerance with prolonged use. Tolerance means the original benefit may lessen over time, which is why periodic re-evaluation is necessary.

Q: Are there any specific liver or kidney conditions that restrict the use of this medicine?

A: Regulatory documents advise caution for patients with kidney issues, specifically severe renal impairment. In these cases, reduced doses may be considered by a prescriber. Use is generally not recommended in those with End-Stage Renal Disease (ESRD). The official labeling does not specifically address liver conditions as a contraindication.

Q: What factors might influence how long the effects of Amphetamine Sulfate last?

A: The duration of the drug’s effects is influenced by factors described in official pharmacokinetic studies. These factors include the drug formulation (immediate-release vs. extended-release) and the acidity or alkalinity (pH level) of the stomach and urine, which is known to influence how the body handles the medication.

Q: How does the immediate-release form of Amphetamine Sulfate differ from the extended-release form?

A: Regulatory documents describe two main oral forms: immediate-release (IR) and extended-release (ER). The IR form releases the medication quickly for a shorter effect, usually lasting 4–6 hours. The ER form is designed to release medication gradually over time, providing a longer duration of action (e.g., 12–16 hours) suitable for once-daily dosing.

Q: Is Amphetamine Sulfate the same thing as Adderall?

A: Amphetamine Sulfate is one of the active amphetamine salts available both as a single-entity drug (like Evekeo) and as a component of other stimulant medications. For example, the product Adderall contains a mix of four different amphetamine salts, one of which is Amphetamine Sulfate.

Q: How long does Amphetamine Sulfate typically take to start working?

A: Pharmacokinetic studies summarized in the regulatory labeling show that for the immediate-release tablets, the drug reaches its highest concentration in the bloodstream approximately three hours after administration. This concentration is typically associated with the peak of the drug's effect.

Q: What happens if a scheduled dose of Amphetamine Sulfate is missed?

A: Official patient counseling information advises taking a missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed one is typically advised to be skipped to maintain the regular schedule. Late evening doses are generally advised to be strictly avoided to prevent disruption of sleep.

Q: Do official regulatory agencies list withdrawal symptoms for Amphetamine Sulfate?

A: Official product labeling warns that stopping the medication abruptly after prolonged high-dose use can lead to specific symptoms. These documented effects of cessation include severe fatigue and mental depression.

Q: What is meant by the 'half-life' of Amphetamine Sulfate?

A: The half-life, reported in the official pharmacokinetics section, is the time required for the concentration of the drug in the blood to decrease by half. For Amphetamine Sulfate, the two active components have half-lives ranging from approximately 9 to 14 hours. This measure is used to understand how long the medication stays in the body.

Q: What kind of monitoring is typically involved for someone taking Amphetamine Sulfate?

A: Regulatory documents recommend regular monitoring of vital signs, including blood pressure and heart rate, throughout treatment. For children, height and weight (growth) should also be monitored. Additionally, patients are routinely screened for abuse risk and pre-existing heart or psychiatric conditions.

Q: Are there warnings about driving or operating machinery while taking Amphetamine Sulfate?

A: Yes, the official patient information advises caution regarding certain activities. The product information contains cautions regarding engagement in potentially hazardous activities, such as operating vehicles or machinery.

Q: Does Amphetamine Sulfate have a Black Box Warning, and what does it concern?

A: Yes, the product labeling includes a Boxed Warning—the most serious warning issued by the FDA. This warning highlights the high potential for drug abuse and dependence. It also alerts patients to the risk of sudden death and serious cardiovascular adverse events that can occur with the misuse of amphetamines.

Q: What are the signs that Amphetamine Sulfate might not be working as expected?

A: The patient counseling section indicates that consultation with a healthcare provider is generally recommended if the medication is not producing expected effects after several weeks of use. This prompt is intended to encourage a re-evaluation of the treatment plan.

Q: What should a person do if they suspect a serious interaction with Amphetamine Sulfate?

A: Official safety information emphasizes the importance of promptly reporting symptoms suggestive of a serious interaction or adverse effect to a healthcare professional. Serious symptoms to report include chest pain, unexplained fainting, or the appearance of new or worsening mental health symptoms.

Q: What is the general patient expectation for follow-up visits when taking this drug?

A: Regulatory documents advise that the need for continued treatment should be periodically assessed by the prescriber. This requirement implies a patient expectation for regular follow-up visits to re-evaluate the ongoing necessity and effectiveness of the medication.

Q: Is Amphetamine Sulfate used for performance enhancement, and what do official sources say about this?

A: Official product warnings caution strongly against the non-therapeutic use and diversion of this medication. The Boxed Warning highlights that misuse can lead to serious adverse events and dependence, and official safety warnings highlight that use outside of approved medical indications is considered misuse.

Q: Does Amphetamine Sulfate have the potential to interact with herbal supplements?

A: Official drug interaction data warns about combining the medication with agents that affect serotonin levels (such as St. John's Wort) or other stimulants. Patients are strongly advised to inform their healthcare provider of all herbal supplements being taken, as some may carry an interaction risk.

Q: What is the official recommended action if side effects occur?

A: The product labeling emphasizes the importance of contacting a healthcare provider promptly if serious adverse reactions are suspected. This includes symptoms related to heart problems (such as chest pain) or new, unusual, or worsening psychiatric symptoms.

How should Amphetamine Sulfate be stored and disposed of?

Official Storage and Disposal Requirements

Amphetamine sulfate must be stored and disposed of according to federal and state regulations for a Schedule II controlled substance.

Storage and Handling

Requirement	Details
Security	Store in a safe, secured, and preferably locked location, out of reach of children and pets.
Conditions	Store at ambient temperatures and keep the container tightly closed.
Protection	The drug must be protected from exposure to light and moisture to maintain stability.

Disposal Protocol

Unused medication should be disposed of via a drug take-back program or an authorized collector as the primary method. If no take-back option is available, the medication should be removed from its original container, mixed with an undesirable substance (like coffee grounds), placed in a sealed bag, and discarded with the household trash. The tablets are not recommended for flushing down the toilet.

Amphetamine Sulfate